Recombinant Expression

Recombinant expression makes a peptide by biology rather than chemistry. The coding sequence, usually fused to a carrier protein that improves yield and shields the product from host proteases, is inserted into an expression host such as Escherichia coli or a yeast, and the host is grown by fermentation. The fusion partner is then removed enzymatically or chemically and the released peptide purified through a chromatographic train of its own.

The approach dominates above the length at which stepwise chemical assembly becomes impractical. Recombinant human insulin, approved in 1982, was the first therapeutic protein produced this way, and somatropin has been made in microbial systems ever since. Semi-synthetic routes are common for modern analogues: a backbone is expressed by fermentation, then a fatty-acid side chain or other non-natural feature is attached chemically afterwards.

Ribosomal synthesis buys homogeneity at the cost of chemical vocabulary. There is no ladder of deletion and truncation impurities, because the ribosome either completes the chain or does not, but D-amino acids, most non-natural residues and a C-terminal amide cannot be installed by translation directly. The impurity profile is replaced rather than eliminated: host cell proteins, host DNA and endotoxin take over from synthesis by-products.

Two claims deserve scepticism. The first is that a recombinant origin implies safety; host cell protein carryover is a principal driver of immunogenicity in protein products, and a Gram-negative host makes endotoxin control mandatory rather than optional. The second is the word itself on a research listing, where it is frequently decorative and unaccompanied by the host-cell or endotoxin data that would give it any meaning.